HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAapproval72% confidence

Clinical trials for medicines: modifying a clinical trial approval

Source: MHRA

Why This Matters

Why this matters: sets a approval precedent in the same sub-indication (immunology) as Roche.

Regulatory Analysis

Guidance on the various types of modifications that can be made to a clinical trial approval.

Supporting Context

Therapeutic area
Oncology · Diagnostics and Multiple Sclerosis · BTK Inhibitor
Sub-indication
Immunology

Related signal: Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics

Source

View source document

Related Signal

Open signal — Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.